ReviewInternational ophthalmology2025
Advances in the treatment of blinding retinal diseases.
Review in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Blinding retinal diseases, including inherited and degenerative conditions, rank globally among the primary causes of permanent vision loss. While certain degenerative retinal diseases like age-related macular degeneration and diabetic retinopathy can be partially managed through intravitreal anti-VEGF injections or the use of complement inhibitors, most patients still lack effective treatment options. Recently, several promising therapeutic avenues have surfaced, such as stem cell-derived retinal pigment epithelium cell transplantation, gene therapy, and the implantation of retinal prostheses. This review summarizes recent clinical trials and advances in gene therapy for inherited retinal diseases, outlines techniques for retinal pigment epithelium cell transplantation, and discusses methods to improve graft survival. It also examines strategies for enhancing the resolution of retinal prostheses and explores their future clinical potential, providing new perspectives on the management of degenerative retinal conditions.
Indexed as
Identifiers
41396384What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.